In chronic hepatitis B, two studies have been carried out comparing Pegasys with lamivudine (another antiviral medicine) in 820 ‘ HBeAg-positive’ patients (infected with the common type of the hepatitis B virus) and in 552 ‘ HBeAg-negative ’ patients (infected with a virus that has mutated [changed], leading to a form of chronic hepatitis B that is more difficult to treat).
Pegasysi võrreldi lamivudiiniga (samuti viiruseravim) 820 HBeAg- positiivsel patsiendil (nakatunud tavalise B- hepatiidi viirusega) ja 552 HBeAg- negatiivsel patsiendil (nakatunud muteerunud viirusega, mille tekitatud krooniline B - hepatiit on raskemini ravitav).